Immunology and Biotherapies
37.5K views | +5 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular.

Gilbert C FAURE's insight:

We use Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...                                                            Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further information on Immune monitoring of Immune therapies, 

http://www.scoop.it/t/immune-monitoring-1     by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

Thanks to K Maggon for joining us. @Krishan Maggon

 

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Tizveni | European Medicines Agency

OverviewOn 22 February 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tizveni, intended for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) either in monotherapy or in combination with chemotherapy. The applicant for this medicinal product is Beigene Ireland Limited.Tizveni will be available as a 100 mg concentrate for solution for infusion. The active substance of Tizveni is tislelizumab, an antineoplastic agent (ATC code: L01FF09). Tislelizumab is a humanised IgG4 variant monoclonal antibody that potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.The benefit of Tizveni is an improvement in overall survival and progression free survival in patients with locally advanced or metastatic NSCLC, as shown in three open-label, randomised phase 3 studies comparing Tizveni (either in monotherapy or in combination) with chemotherapy. The most common side effects are anaemia, fatigue and increased AST.The full indication is:Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have:locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, ormetastatic NSCLC.Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have:locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, ormetastatic NSCLC.Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.Tizveni should be prescribed by physicians experienced in the treatment of cancer.Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.CHMP summary of positive opinion for TizveniAdoptedFirst published: 23/02/2024Reference Number: EMA/CHMP/59203/2024 English (EN) (114.24 KB - PDF)ViewProduct detailsName of medicine Tizveni Active substance Tislelizumab International non-proprietary name (INN) or common name tislelizumab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01FF09 EMA product number EMEA/H/C/005542 Marketing authorisation applicant BeiGene Ireland Ltd Opinion adopted 22/02/2024 Opinion status Positive This page was last updated on 23/02/2024Share this page
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Arnaud Delobel on LinkedIn: #cancertherapy #fdaapproval #tiltherapy #medicalinnovation…

Arnaud Delobel on LinkedIn: #cancertherapy #fdaapproval #tiltherapy #medicalinnovation… | Immunology and Biotherapies | Scoop.it
The FDA has just approved a revolutionary Tumor-Infiltrating Lymphocytes (TIL) therapy from Iovance Biotherapeutics, Inc.! But what exactly are TILs? 🤔

🔬…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Jean Daniel Lelièvre sur LinkedIn : Webinaire vaccin grippe One Health 1 Oiseaux et hommes partage de…

Jean Daniel Lelièvre sur LinkedIn : Webinaire vaccin grippe One Health 1 Oiseaux et hommes partage de… | Immunology and Biotherapies | Scoop.it
Les présentations du "Webinaire vaccin anti grippe" One Health organisé par le DIM One Health 2.0 et le club de vaccinologie de la SFI sont désormais…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Jeroen Wissink on LinkedIn: Cancer vaccines: the next immunotherapy frontier - Nature Cancer

Jeroen Wissink on LinkedIn: Cancer vaccines: the next immunotherapy frontier - Nature Cancer | Immunology and Biotherapies | Scoop.it
💥 How do we measure cancer vaccine immune responses? Is this similar to (simply..) measuring antibody titers, as in prophylactic vaccines? It took some time…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

https://www.nejm.org/doi/full/10.1056/NEJMoa2301790

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CD56bright natural killer cells preferentially kill proliferating CD4+ T cells | Discovery Immunology | Oxford Academic

CD56bright natural killer cells preferentially kill proliferating CD4+ T cells | Discovery Immunology | Oxford Academic | Immunology and Biotherapies | Scoop.it
Abstract. Human CD56br natural killer (NK) cells represent a small subset of CD56+ NK cells in circulation and are largely tissue-resident. The frequency and nu
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Gavi, the Vaccine Alliance on LinkedIn: Vaccine profiles: malaria

Gavi, the Vaccine Alliance on LinkedIn: Vaccine profiles: malaria | Immunology and Biotherapies | Scoop.it
Malaria is thought to be responsible for up to five percent of all human deaths in the 20th Century.

The world now has two vaccines which, alongside other…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR-T hype faces infrastructure reality check

CAR-T hype faces infrastructure reality check | Immunology and Biotherapies | Scoop.it
Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times hindered these cell-based treatments. As biopharma companies clear those hurdles, a larger, more systemic problem now threatens the drug class.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Study shows engineered antibodies significantly boost Omicron neutralization

Study shows engineered antibodies significantly boost Omicron neutralization | Immunology and Biotherapies | Scoop.it
Researchers engineered IgA antibodies from IgG monoclonals, enhancing neutralization against Omicron by up to 75-fold and offering protection in mice models.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Understanding immune checkpoint blockade therapy: a pillar of modern cancer treatment | British Society for Immunology

Understanding immune checkpoint blockade therapy: a pillar of modern cancer treatment | British Society for Immunology | Immunology and Biotherapies | Scoop.it
Checkpoint blockade immunotherapy has marked a turning point in the fight against cancer. It has not only transformed scientific thinking of how our bodies can respond to cancer but has also shown us that it can be possible to tackle cancers we previously viewed as untreatable.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cancers | Free Full-Text | Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy

Cancers | Free Full-Text | Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy | Immunology and Biotherapies | Scoop.it
Regulatory T cells (Tregs) are fundamental to maintaining immune homeostasis by inhibiting immune responses to self-antigens and preventing the excessive activation of the immune system. Their functions extend beyond immune surveillance and subpopulations of tissue-resident Treg cells can also...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Juan Lama on LinkedIn: Scientists Identify Interferon-gamma as Potential SARS-CoV-2 Antiviral

Juan Lama on LinkedIn: Scientists Identify Interferon-gamma as Potential SARS-CoV-2 Antiviral | Immunology and Biotherapies | Scoop.it
NIH and New Zealand researchers show how conditioning the lungs with interferon-gamma, a natural immune system protein best known for fighting bacterial…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Sickle cell disease gene therapies Casgevy Lyfgenia insurance cost issues

Sickle cell disease gene therapies Casgevy Lyfgenia insurance cost issues | Immunology and Biotherapies | Scoop.it
Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Powerful new antivenom raises hopes for a universal solution to lethal snakebites

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Bernard Maillere on LinkedIn: The target atlas for antibody-drug conjugates across solid cancers -…

Bernard Maillere on LinkedIn: The target atlas for antibody-drug conjugates across solid cancers -… | Immunology and Biotherapies | Scoop.it
interesting overview of the worldwide compétition for ADC. hard to find a place for a new product.
No comment yet.
Rescooped by Gilbert C FAURE from Virus World
Scoop.it!

COVID-19 and Flu-Ravaged Lungs Could Be Repaired with mRNA Therapy

COVID-19 and Flu-Ravaged Lungs Could Be Repaired with mRNA Therapy | Immunology and Biotherapies | Scoop.it

Repair of lung injury due to viral infection can be facilitated by nanoparticle-delivered mRNA targeting TGF-βR2 signaling. Respiratory infections, such as those caused by SARS-CoV-2 or influenza, can damage the lungs’ delicate network of capillary blood vessels, compromising oxygen delivery and carbon dioxide removal. To overcome this damage, the lungs depend on the regenerative capacities of vascular endothelial cells. As valuable as these cells are, they can, according to University of Pennsylvania scientists, benefit from a little help. The scientists, led by Andrew Vaughan, PhD, focused on a repair pathway involving vascular endothelial growth factor α (Vegfa) and the TGF-β receptor 2 (TGF-βR2). Using animal models and human tissue samples, the scientists showed that delivering Vegfa via lipid nanoparticles (LNPs) greatly enhances modes of repair for damaged blood vessels. “Mice deficient in endothelial Tgfbr2 exhibited prolonged injury and diminished vascular repair,” the article’s authors wrote. “Loss of endothelial Tgfbr2 prevented autocrine Vegfa expression, reduced endothelial proliferation, and impaired renewal of aerocytes thought to be critical for alveolar gas exchange.” “We developed a lipid nanoparticle that targets the pulmonary endothelium, Lung-LNP (LuLNP),” the authors continued. “Delivery of Vegfa mRNA, a critical TGF-βR2 downstream effector, by LuLNPs improved the impaired regeneration phenotype of endothelial cell Tgfbr2 deficiency during influenza injury.”

 

Vaughan’s team and other investigators had previously shown that endothelial cells are among the unsung heroes in repairing the lungs after viral infections. But Vaughan’s team noted that its work demonstrated that a “more granular understanding of the fundamental mechanisms driving reconstitution of lung endothelium” could inform efforts to facilitate therapeutic vascular repair. “Here we’ve identified and isolated pathways involved in repairing this tissue, delivered mRNA to endothelial cells, and consequently observed enhanced recovery of the damaged tissue,” Vaughan said. “These findings hint at a more efficient way to promote lung recovery after diseases like COVID-19.” The team found Vegfa’s involvement in this recovery, while building on work in which they used single-cell RNA sequencing to identify TGF-βR2 as a major signaling pathway. The researchers saw that when TGF-βR2 was missing, it stopped the activation of Vegfa. This lack of signal made the blood vessel cells less able to multiply and renew themselves, which is vital for the exchange of oxygen and carbon dioxide in the tiny air sacs of the lungs. “We’d known there was a link between these two pathways, but this motivated us to see if delivering Vegfa mRNA into endothelial cells could improve lung recovery after disease-related injury,” said first author Gan Zhao, PhD, a postdoctoral researcher in the Vaughan laboratory. The Vaughan laboratory then reached out to Michael J. Mitchell, PhD, of the School of Engineering and Applied Science, whose laboratory specializes in LNPs, to see if delivery of this mRNA cargo would be feasible.

 

“LNPs have been great for vaccine delivery and have proven incredibly effective delivery vehicles for genetic information,” said Mitchell, who is an associate professor of bioengineering at Penn Engineering and a co-author of the paper. “But the challenge here was to get the LNPs into the bloodstream without them heading to the liver, which is where they tend to congregate as its porous structure lends favor to substances passing from the blood into hepatic cells for filtration. So, we had to devise a way to specifically target the endothelial cells in the lungs.” The Mitchell laboratory’s LNPs proved effective in delivering Vegfa into endothelial cells, and as a result, the researchers saw a marked improvement in vascular recovery in their animal models. Within the animal models, the researchers saw improved oxygen levels, and in some, the treatment helped them recover their weight better than the control group. These treated mice also had less lung inflammation, shown by lower levels of certain markers in their lung fluid, and their lungs showed less damage and scarring, with more healthy blood vessels. “We’re looking forward to testing this delivery platform for other cell types in the lung, and it will be important to evaluate whether TGF-βR2 signaling is important in other injury contexts including chronic conditions like emphysema and chronic obstructive pulmonary disease,” Vaughan said. “With this proof-of-concept being well validated, we’re sure that we’ll pave the way for new mRNA-based strategies for treating lung injury.”

 

Published in January 31, 2024 in Science Translational Med:

https://doi.org/10.1126/scitranslmed.adg6229 


Via Juan Lama
Sos's curator insight, February 15, 8:03 PM

Amazing

 

https://buypsychedelicdrugs.com/product-category/dmt/

https://buypsychedelicdrugs.com/product/5-meo-dmt/

https://buypsychedelicdrugs.com/product/4-aco-dmt/

https://buypsychedelicdrugs.com/product/ayahuasca/

https://buypsychedelicdrugs.com/product/changa-dmt/

https://buypsychedelicdrugs.com/product/buy-dmt-vape-pen/

https://buypsychedelicdrugs.com/product/lsd-tabs/

https://buypsychedelicdrugs.com/product/buy-mimosa-hostilis-root-bark-powdered-mhrb/

https://buypsychedelicdrugs.com/product/nn-dmt/

https://buypsychedelicdrugs.com/product/amanita-muscaria/

https://buypsychedelicdrugs.com/product/buy-dragons-dynamite-truffles/

https://buypsychedelicdrugs.com/product/golden-teachers/

https://buypsychedelicdrugs.com/product/buy-high-hawaiians-truffles/

https://buypsychedelicdrugs.com/product/liberty-caps/

https://buypsychedelicdrugs.com/product/buy-microdosing-psilocybin-truffles-10-pack/

https://buypsychedelicdrugs.com/product/buy-microdosing-psilocybin-truffles-2-pack-in-stock/

https://buypsychedelicdrugs.com/product/buy-microdosing-psilocybin-truffles-20-pack/

https://buypsychedelicdrugs.com/product/golden-teachers/

https://buypsychedelicdrugs.com/product/buy-penis-envy-mushroom/

https://buypsychedelicdrugs.com/product/codeine-promethazine/

https://buypsychedelicdrugs.com/product/ecstasy-mdma/

https://buypsychedelicdrugs.com/product/microdosing-psilocybin-truffles-1-pack-for-sale/

https://buypsychedelicdrugs.com/product/mush-rocks-truffles-for-sale/

https://buypsychedelicdrugs.com/product/pcp-powder/

https://buypsychedelicdrugs.com/product/cocaine/

https://buypsychedelicdrugs.com/product/methamphetamine/

https://buypsychedelicdrugs.com/product/xanax/

https://buypsychedelicdrugs.com/product/lsd-gel-tabs/

https://buypsychedelicdrugs.com/product/lsd-liquid/

 

 

https://caluaniemuelearoxidizeusa.com/product/buy-10l-caluanie-muelear-pasteurize/

https://caluaniemuelearoxidizeusa.com/product/buy-20l-caluanie-muelear-oxidize/

https://caluaniemuelearoxidizeusa.com/product/buy-5l-caluanie-muelear-pasteurize/

https://caluaniemuelearoxidizeusa.com/product/buy-caluanie-muelear-pasteurize/

Scooped by Gilbert C FAURE
Scoop.it!

Andrew Pannu sur LinkedIn : Is the best yet to come for cell therapy? I pulled together 45 companies… | 47 commentaires

Andrew Pannu sur LinkedIn : Is the best yet to come for cell therapy? I pulled together 45 companies… | 47 commentaires | Immunology and Biotherapies | Scoop.it
Is the best yet to come for cell therapy?

I pulled together 45 companies in the space and charted the preclinical and clinical assets of each, segmented by… | 47 commentaires sur LinkedIn
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer | Clinical and Experimental Immunology | Oxford Academic

Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer | Clinical and Experimental Immunology | Oxford Academic | Immunology and Biotherapies | Scoop.it
Natural Killer (NK) cells exert an important role in cancer immune surveillance and recognition of malignant cells as well as their controlled activation is fac
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

“The vaccine is extremely effective”: no cases of invasive cervical cancer found in Scottish women vaccinated against HPV | Gavi, the Vaccine Alliance

“The vaccine is extremely effective”: no cases of invasive cervical cancer found in Scottish women vaccinated against HPV | Gavi, the Vaccine Alliance | Immunology and Biotherapies | Scoop.it
Real-world data suggests the HPV vaccine dramatically cuts cancer risk among women who received it during adolescence.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR-T cell manufacturing: Major process parameters and next-generation strategies | Journal of Experimental Medicine | Rockefeller University Press

The success of CAR-T cell therapies is dependent on effective cell manufacturing that impacts product safety, efficacy, and patient accessibility. Here, we disc
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma | Scientific Reports

Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma | Scientific Reports | Immunology and Biotherapies | Scoop.it
Human Vγ9Vδ2 T lymphocytes are regarded as promising effector cells for cancer immunotherapy since they have the ability to eliminate several tumor cells through non-peptide antigen recognition. However, the cytotoxic function and the mechanism of Vγ9Vδ2 T cells leading to specific killing of...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

John Gordon en LinkedIn: Structural basis for the activity and specificity of the immune checkpoint…

John Gordon en LinkedIn: Structural basis for the activity and specificity of the immune checkpoint… | Immunology and Biotherapies | Scoop.it
#Immunotherapy | How #Lirilumab #KIR-tails an #ImmuneCheckpoint | New OPEN ACCESS Study by Nicholas Lorig-Roach et al Unveils General Concepts for the…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Vaccines | Free Full-Text | HBV Vaccines: Advances and Development

Vaccines | Free Full-Text | HBV Vaccines: Advances and Development | Immunology and Biotherapies | Scoop.it
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as a result of the introduction of universal...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

IJMS | Free Full-Text | Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals

IJMS | Free Full-Text | Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals | Immunology and Biotherapies | Scoop.it
Plants are increasingly used for the production of high-quality biological molecules for use as pharmaceuticals and biomaterials in industry. Plants have proved that they can produce life-saving therapeutic proteins (Elelyso™—Gaucher’s disease treatment, ZMapp™—anti-Ebola monoclonal antibodies,...
No comment yet.
Rescooped by Gilbert C FAURE from Virus World
Scoop.it!

‘It’s All Gone’: CAR-T Therapy Forces Autoimmune Diseases into Remission

‘It’s All Gone’: CAR-T Therapy Forces Autoimmune Diseases into Remission | Immunology and Biotherapies | Scoop.it

Engineered immune cells have given 15 people with once-debilitating autoimmune disorders a new lease on life, free from fresh symptoms or treatments. The results raise hopes that the approach — called CAR-T-cell therapy — might one day be extended to a variety of other conditions fuelled by rogue immune cells that produce antibodies against the body’s own tissues. All 15 participants, who each had one of three autoimmune conditions, have remained disease-free or nearly so since their treatment, according to data presented on 9 December at the American Society of Hematology meeting in San Diego, California. The first participants were treated more than two years ago. These successes, although preliminary, have been electric, says Marco Ruella, an oncologist at the University of Pennsylvania in Philadelphia. “We’re all excited,” he says. “There’s a lot of potential.”

Bespoke immune cells

CAR-T therapies harness the immune players called T cells. T cells are removed from the person being treated, genetically engineered to produce proteins called chimeric antigen receptors (CARs) and then reintroduced to the person’s body. In many therapies, the T cells are tailored to recognize a protein made by immune cells called B cells. When reintroduced, the CAR T cells will target the B cells for destruction — a useful feature for treating cancers caused by abnormal B cells. B cells also drive some autoimmune disorders by making antibodies that attack healthy tissue. In 2019, researchers showed that CAR T cells that recognize B cells reduced symptoms in mice with a disease similar to lupus, an autoimmune disorder that affects a variety of organs1. Around the same time, researchers at University Hospital Erlangen in Germany were setting up their own CAR-T centre to provide cancer treatment. During a meeting at the centre, a rheumatologist asked the cancer specialists for advice about a young woman with a form of lupus called systemic lupus erythematosus. Several of her organs were failing; her doctors estimated that she did not have long to live. The young woman insisted that they try something new.

High-risk approach

The team thought of the mouse study but baulked at trying it in people. CAR-T therapy can have severe side effects, and recipients must first undergo intensive chemotherapy that kills off many of their existing immune cells. “At the beginning we were quite scared,” said team member Fabian Müller, an oncologist at the Friedrich–Alexander University of Erlangen–Nuremberg, at a press conference before he presented the work at the San Diego meeting. The woman was adamant that they try. That first participant — and the others who followed — experienced relatively minor adverse effects, Müller reported at the conference. The Erlangen team eventually used the method to treat two other autoimmune disorders: systemic sclerosis and idiopathic inflammatory myositis. The successes continued. Other groups have since taken up the approach and reported similar results. Earlier this month, another team added a fourth autoimmune disorder called myasthenia gravis to the list of successes2. Researchers are beginning to wonder how long the final list will be. “We’re just at the beginning,” says Marcela Maus, who designs CAR-T therapies against cancer at Massachusetts General Hospital in Boston. “There is so much that can be done that was unthinkable just a decade ago.” At this stage, however, it’s unclear how much of this success is due to the CAR-T therapy as opposed to the chemotherapy that killed many of the participants’ pre-existing immune cells, cautions Ruella. That might have helped to wipe out the errant B cells. For now, Müller lapses into a dreamy smile as he marvels over the remarkable recoveries he has seen: the man who struggled to walk 10 metres before his treatment and now routinely walks 10 kilometres around town, for example. “These are young people that have been spending more time with their doctors than with their friends,” he says. “They would describe their breakfast as a handful of pills that they are just shoving in.”

“And it’s all gone,” he says. “From the physician perspective, it’s pretty much the most pleasing thing.”

 

December 12, 2023

https://doi.org/10.1038/d41586-023-03968-6

 


Via Juan Lama
No comment yet.